Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This is a randomized controlled study. Baricitinib 4mg in one arm and Baricitinib 2mg in
another arm will be used. Methotrexate 10mg per week in both arms will be used.
Phase:
Phase 4
Details
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh